COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson’s disease
Authors:
- 26 February 2002
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Neurology
- Vol. 58 (4) , 564-567
Abstract
Objective: To investigate the relationship between the catechol-O-methyltransferase (COMT) genotype and the therapeutic efficacy of entacapone. Methods: The efficacy of 2 months of entacapone treatment in 65 patients with PD with end-of-dose deterioration was studied. The efficacy of entacapone was assessed using the Unified Parkinson’s Disease Rating Scale (UPDRS) score, the daily levodopa dosage, and the patients’ diary card. Results: Thirty-six patients (55.4%) had a high-activity COMT gene (COMTHH), 22 (33.8%) had an intermediate-activity COMT gene (COMTHL), and 7 patients (10.8%) had a low-activity COMT gene (COMTLL). Two months of entacapone treatment resulted in a significant increase in “on” time, a reduction in “off” time, and a reduction in the total UPDRS score, but these results were independent of the COMT genotype of the patient. There was no significant difference in the frequency or severity of dyskinesias between the patients with different COMT genotypes. Conclusion: The COMT genotype seems to be a minor factor in judging the beneficial effects of entacapone administration.Keywords
This publication has 17 references indexed in Scilit:
- The Relationship between COMT Genotype and the Clinical Effectiveness of Tolcapone, a COMT Inhibitor, in Patients with Parkinson's DiseaseClinical Neuropharmacology, 2000
- Catechol-O-methyltransferase genotype and susceptibility to Parkinson's disease in JapanJournal of Neural Transmission, 1997
- G/A1947 polymorphism in catechol‐O‐methyltransferase (COMT) gene in Parkinson's diseaseMovement Disorders, 1997
- Genetic polymorphism of catechol-O-methyltransferase (COMT): correlation of genotype with individual variation of S-COMT activity and comparison of the allele frequencies in the normal population and Parkinsonian patients in FinlandPharmacogenetics, 1997
- Emerging Treatments in Parkinson's DiseaseEuropean Neurology, 1997
- Kinetics of Human Soluble and Membrane-Bound Catechol O-Methyltransferase: A Revised Mechanism and Description of the Thermolabile Variant of the EnzymeBiochemistry, 1995
- Inhibition of catechol-O-methyltransferase activity by two novel disubstituted catechols in the ratEuropean Journal of Pharmacology, 1988
- The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.Journal of Neurology, Neurosurgery & Psychiatry, 1988
- 3‐O‐Methyldopa and the response to levodopa in Parkinson's diseaseAnnals of Neurology, 1987
- Pharmacokinetics of LevodopaClinical Neuropharmacology, 1984